Trade Mark Journal No.2026/038 18 September 2026

WO0000001935811 (1,5,42)

Office of origin: Switzerland

Date of International Registration:18 June 2026
Date of designation in the UK: 18 June 2026
Image for mark 1935811_TIF GS Ori-Go

International priority date claimed: 27 April 2026 (Switzerland) (850575)
Class 1
Cells for scientific, laboratory, medical research and clinical use including genetic material for protein production; biological preparations, not for medical use, namely, genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial use in scientific research, and for use in pharmaceutical research; kits consisting of cell lines, reagents, enzyme substrates and/or genetically modified chemical preparations; reagents, nucleic acids and nucleotides for scientific use and for research purposes in the field of clinical research, drug development, research in agriculture and genetics; reagent kits consisting of reagents and chemical preparations; samples of nucleotide sequence variants and modifications for use in the field of scientific research, clinical research and scientific research in diagnosis.
Class 5
Biological preparations, for medical use, namely, genetically modified cells and genetically modified vectors for production of human, animal and synthetic proteins for medical purposes and, for clinical and commercial use in human and animal therapies; Gene therapy products, namely, modified cells and modified cell platforms.
Class 42
Scientific and medical research in the field of biotechnology; Technical consultancy and project planning in the field of biological research relating to proteins; research and development in the field of proteins for others; scientific research and laboratory services in the fields of editing, modification, engineering and regulation of genes, genome and cells for the development of pharmaceutical and biological preparations for human and veterinary use; aggregating, analyzing and providing data in the field of genomics; custom design and development of cell lines designed for others for scientific research, drug discovery and development; scientific research and laboratory services in the fields of editing, modification, engineering and regulation of genes, genome and cells for the development of medical diagnostic products.

Lonza Ltd.

Representative: von Arx Schmidiger Faber Rechtsanwälte, Neumarkt 15, CH-8401 Winterthur, SWITZERLAND